Upsher-Smith To Buy U.K. Biotech Partner Proximagen For $347 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed acquisition mimics other recent M&A deals, like Sanofi/Genzyme, with inclusion of contingent-value rights pegged to success of two clinical candidates.